PHAXIAM Therapeutics S.A. (PHXM)

Market Cap	28.90M
Revenue (ttm)	6.56M
Net Income (ttm)	-12.53M
Shares Out	6.40M
EPS (ttm)	-3.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	902
Open	3.060
Previous Close	3.270
Day's Range	3.050 - 3.100
52-Week Range	2.500 - 13.000
Beta	1.96
Analysts	n/a
Price Target	n/a
Earnings Date	May 7, 2024

About PHXM

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thir...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: PHXM

Financial Performance

In 2022, PHXM's revenue was 31.00 million, an increase of 641.58% compared to the previous year's 4.18 million. Losses were -228,000, -99.58% less than in 2021.

Financial numbers in EUR